Teva Pharmaceutical Industries Limited

NYSE:TEVA

$17.455 USD

$0.07 (0.43%)

Volume
2.34M
Average Volume
8.32M
Market Capitalization
$19.78B
P/E Ratio
-41.63
Dividend Yield
0.00%
Price Target
$22.00
Year High
$19.08
Year Low
$8.06
Payout Ratio
$0.00
Current Ratio
$0.89

Industry, Sector & symbol

Stock Exchange New York Stock Exchange
CEO Mr. Richard D. Francis
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Current Symbol TEVA
CUSIP 881624209
CIK 0000818686
Web https://www.tevapharm.com
Phone 972 3 914 8213
Currency USD
Employees 35001
Country IL

Liquidity

Debt-to-Equity Ratio 2.93
Payout Ratio 0.00
Current Ratio 0.89
Quick Ratio 0.59
Cash Ratio 0.17

Sales & Book Value

Annual Sales $15.84B
Price / Sales 1.21
Cash Flow 1.14
Price / Cash Flow 15.32
Price / Book 3.11

Price Target and Rating

Average Stock Price Forecast $22.00
High Stock Price Forecast $26.00
Low Stock Price Forecast $10.00
Forecast Upside/Downside -20.66%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 8 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.5
Trailing P/E Ratio -41.63
PEG Ratio -0.54
P/E Growth -0.54
Net Income $-559M
Net Margin -2.91%
Pretax Margin -1.01%
Return on Equity -6.77%
Return on Assets -1.15%

Financials Score

AltmanZ Score 0.47
Piotroski Score 5.00
Working Capital -1.4B
Total Assets 41.34B
Ebit 3.42B
Market Cap 19.69B
Total Liabilities 34.77B

Poll Results

About Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and A ... USTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

2024-10-03 08:30:00

TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

2024-10-01 08:29:00

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin®1 LAR Depot, in the United States.

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

2024-09-30 16:30:00

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Medincell's Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

2024-09-23 02:00:00

MONTPELLIER, France--(BUSINESS WIRE)--New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercialization. Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY f.

Medincell's Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia

2024-09-23 02:00:00

MONTPELLIER, France--(BUSINESS WIRE)--Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in adult patients diagnosed with schizophrenia. Richard Malamut, Chief Medical Officer of Medincell, said: “In addition to publishing the positive efficacy results for the primary and secondary endpoints of the SOLARIS study, the data presented by Teva unveiled the three doses evaluated, which align wit.

Frequently Asked Questions

What is the current Teva Pharmaceutical Industries Limited (TEVA) stock price?

Teva Pharmaceutical Industries Limited(NYSE:TEVA) stock price is $17.455 in the last trading session. During the trading session, TEVA stock reached the peak price of $19.08 while $8.06 was the lowest point it dropped to. The percentage change in TEVA stock occurred in the recent session was 0.43% while the dollar amount for the price change in TEVA stock was $0.07.

TEVA's industry and sector of operation?

The NYSE listed TEVA is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of TEVA?

Mr. Richard Gordon Daniell | Executive Vice President of European Commercial
Mr. Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer
Mr. Kevin C. Mannix | Senior Vice President of Investor Relations
Mr. Mark Sabag | Executive Vice President of International Markets Commercial
Mr. David R. Mcavoy J.D. | Executive Vice President & Chief Legal Officer

How many employees does TEVA have?

Number of TEVA employees currently stands at 35001. TEVA operates from 124 Dvora Hanevi’a Street, Tel Aviv, None 6944020, IL.

Link for TEVA official website?

Official Website of TEVA is: https://www.tevapharm.com

How do I contact TEVA?

TEVA could be contacted at phone #972 3 914 8213 and can also be accessed through its website. TEVA operates from 124 Dvora Hanevi’a Street, Tel Aviv, None 6944020, IL.

How many shares of TEVA are traded daily?

The average number of TEVA shares traded daily for last 3 months was 8.32M.

What is the market cap of TEVA currently?

The market value of TEVA currently stands at $19.78B with its latest stock price at $17.455